Ulotaront vs Standard of Care on Weight Parameters in Schizophrenia

Phase 1, randomised, double-blind trial of ulotaront in schizophrenia (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Insulin stimulated change in glucose disposal rate during the steady state of the low dose hyperinsulinemic euglycemic clamp (HEC) at 8 weeks, Insulin stimulated change in glucose disposal rate during the steady state of the high dose hyperinsulinemic euglycemic clamp (HEC) at 8 weeks and 4 more. Started Nov 2022; status: completed.